Capsule with ome 20
Pro Research Analysisby 
Searched over 200M research papers
Bioavailability and Bioequivalence of Omeprazole 20 mg Capsules
Introduction to Omeprazole 20 mg Capsules
Omeprazole is a widely used proton-pump inhibitor (PPI) that reduces stomach acid production, commonly prescribed for conditions such as gastritis, reflux, and heartburn. Various formulations of omeprazole 20 mg capsules are available, and their bioavailability and bioequivalence are critical for ensuring therapeutic efficacy and safety.
Bioavailability of Omeprazole 20 mg Capsules
Enteric-Coated Pellets in Omeprazole Capsules
A study conducted in Bangladesh compared the bioavailability of omeprazole 20 mg capsules containing 22.5% enteric-coated pellets (Xeldrin®20) with a reference product (Losec®20). The study found that both formulations met the FDA criteria for bioequivalence, with no significant differences in pharmacokinetic parameters such as Cmax, Tmax, and AUC between the test and reference products.
Omeprazole with Sodium Bicarbonate
In Mexico, a bioequivalence study of omeprazole 20 mg combined with sodium bicarbonate (1100 mg) showed that this formulation is effective for treating acid-related disorders. The combination helps in immediate release and rapid action, making it suitable for conditions requiring quick relief.
Comparative Bioequivalence Studies
Healthy Volunteers in Different Populations
Several studies have been conducted to compare the bioequivalence of different omeprazole 20 mg capsule formulations in various populations:
- Bangladeshi Subjects: The study mentioned earlier confirmed bioequivalence between Xeldrin®20 and Losec®20 in healthy Bangladeshi male subjects.
- Mexican Volunteers: A study in Mexico compared two oral formulations of omeprazole 20 mg and found them to be bioequivalent, with no significant adverse effects reported.
- Korean Volunteers: In a study involving healthy Korean male volunteers, two brands of omeprazole 20 mg capsules were found to be bioequivalent, with pharmacokinetic parameters falling within the FDA's acceptable range.
- Algerian Volunteers: A pilot study in Algeria found that two brands of omeprazole 20 mg gastro-resistant capsules were not bioequivalent during fasting state, as the Cmax did not fall within the bioequivalence acceptance range.
Repeated-Dose Studies
A study involving healthy volunteers treated with omeprazole 20 mg capsules for six consecutive days showed that the test and reference formulations were bioequivalent in terms of both the rate and extent of bioavailability.
Pharmacokinetic Comparisons
Delayed-Release Capsules vs. Simplified Suspension
A comparison between omeprazole delayed-release capsules and a simplified omeprazole suspension (SOS) revealed that while the SOS had a faster absorption rate, the overall bioavailability was lower compared to the capsule formulation. This suggests that the capsule form may be more effective for sustained therapeutic levels.
Enteric-Coated Tablets vs. Capsules
In a study comparing the pharmacokinetics of omeprazole 20 mg enteric-coated tablets and capsules in duodenal ulcer patients, the tablet formulation showed higher bioavailability and a longer Tmax compared to the capsule, indicating a potential advantage in maintaining therapeutic levels over time.
Stability of Omeprazole Capsules
A stability study of omeprazole capsules containing enteric-coated pellets from various pharmaceutical laboratories in Argentina found that the stability of omeprazole depends significantly on the formulation and primary container. Proper formulation is crucial to maintaining the drug's efficacy over time.
Conclusion
The bioavailability and bioequivalence of omeprazole 20 mg capsules are well-documented across various formulations and populations. Most studies confirm that different brands and formulations meet the FDA criteria for bioequivalence, ensuring their therapeutic efficacy. However, individual differences and specific formulation characteristics can influence the pharmacokinetic profiles, highlighting the importance of rigorous testing and quality control in the production of omeprazole capsules.
Sources and full results
Most relevant research papers on this topic